**Question:** Activator of acetyl CoA carboxylase is

A. Insulin
B. Glucagon
C. Decreased AMP levels
D. Decreased AMP-activated protein kinase activity

**Core Concept:**
Acetyl-CoA carboxylase (ACC) is a rate-limiting enzyme in fatty acid synthesis, catalyzing the carboxylation of acetyl-CoA to form malonyl-CoA. Malonyl-CoA inhibits carnitine palmitoyltransferase-1 (CPT-1), which is responsible for the entry of long-chain fatty acids into the mitochondria for beta-oxidation. Thus, an activator of ACC would lead to increased malonyl-CoA levels, inhibiting fatty acid oxidation and promoting fatty acid synthesis.

**Why the Correct Answer is Right:**
The correct answer is D, decreased AMP-activated protein kinase (AMPK) activity. AMPK is a heterotrimeric enzyme that plays a crucial role in regulating energy homeostasis by modulating ACC activity. In response to increased cellular energy demand or low ATP levels, AMPK is activated, leading to inhibition of ACC and subsequent fatty acid synthesis. Conversely, when ATP levels are high, AMPK is inhibited, allowing ACC activation and fatty acid synthesis.

**Why Each Wrong Option is Incorrect:**
A. Insulin - Insulin acts as an inhibitor of ACC, not an activator. It lowers glucose levels by stimulating glycogen synthesis and inhibiting gluconeogenesis, not promoting fatty acid synthesis.
B. Glucagon - Similar to insulin, glucagon also inhibits ACC. However, its primary action is stimulating glucose production by promoting gluconeogenesis and inhibiting glycogenolysis.
C. Decreased AMP levels - Although AMP levels increase during cellular stress, they are not directly responsible for ACC activation. The correct answer, decreased AMP-activated protein kinase (AMPK) activity, is the key factor.

**Clinical Pearl:**
AMPK activation is vital for maintaining cellular energy homeostasis and preventing excessive lipid accumulation. In clinical scenarios like obesity, type 2 diabetes, or insulin resistance, AMPK activity may be impaired, leading to excessive fatty acid synthesis and increased risk of non-alcoholic fatty liver disease (NAFLD) and cardiovascular diseases. Restoring AMPK activity could be a potential therapeutic target in these conditions.